VTAK vs ATRC vs BEAT vs IRTC vs ELMD

For growth investors, iRhythm Technologies, Inc.

(IRTC) is the stronger pick with 26. 2% revenue growth year-over-year, versus -5. 0% for Catheter Precision, Inc. (VTAK). Electromed, Inc. (ELMD) offers the better valuation at 31. 3x trailing P/E (24. 5x forward), making it the more compelling value choice. Analysts rate AtriCure, Inc. (ATRC) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Electromed, Inc.

is actually cheaper at 24. 5x.

Over the past 5 years, Electromed, Inc.

(ELMD) delivered a total return of +168. 5%, compared to -100. 0% for Catheter Precision, Inc. (VTAK). Over 10 years, the gap is even starker: ELMD returned +484. 2% versus VTAK's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), iRhythm Technologies, Inc.

(IRTC) is the lower-risk stock at 0. 73β versus HeartBeam, Inc. 's 1. 27β — meaning BEAT is approximately 75% more volatile than IRTC relative to the S&P 500. On balance sheet safety, Electromed, Inc. (ELMD) carries a lower debt/equity ratio of 0% versus 5% for iRhythm Technologies, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), iRhythm Technologies, Inc.

(IRTC) is pulling ahead at 26. 2% versus -5. 0% for Catheter Precision, Inc. (VTAK). On earnings-per-share growth, the picture is similar: AtriCure, Inc. grew EPS 74. 7% year-over-year, compared to 15. 1% for HeartBeam, Inc.. Over a 3-year CAGR, VTAK leads at 167. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Electromed, Inc.

(ELMD) is the more profitable company, earning 11. 8% net margin versus -39. 6% for Catheter Precision, Inc. — meaning it keeps 11. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ELMD leads at 15. 1% versus -26. 8% for VTAK. At the gross margin level — before operating expenses — VTAK leads at 90. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Electromed, Inc.

(ELMD) trades at 24. 5x forward P/E versus 27422. 7x for iRhythm Technologies, Inc. — 27398. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATRC: 95. 3% to $51. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, iRhythm Technologies, Inc.

(IRTC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 73), +363. 2% 10Y return). Both have compounded well over 10 years (IRTC: +363. 2%, BEAT: -81. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VTAK is a small-cap quality compounder stock; ATRC is a small-cap quality compounder stock; BEAT is a small-cap quality compounder stock; IRTC is a small-cap high-growth stock; ELMD is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.